(Q39622594)

13 September 2017

title

Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines (English)

1 reference

13 September 2017

Claudia Bocca

1

1 reference

13 September 2017

Francesca Bozzo

series ordinal

2

1 reference

13 September 2017

Andrea Bassignana

series ordinal

3

1 reference

13 September 2017

Antonella Miglietta

series ordinal

4

1 reference

13 September 2017

publication date

8 December 2010

1 reference

Molecular and Cellular Biochemistry

13 September 2017

published in

1 reference

13 September 2017

volume

350

1 reference

13 September 2017

issue

1-2

1 reference

13 September 2017

page(s)

59-70

1 reference

13 September 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Breast cancer risk management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Cyclooxygenase-2: a target for the prevention and treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

COX inhibitors and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Aromatase and COX in breast cancer: enzyme inhibitors and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Cyclooxygenase-2 directly regulates gene expression of P450 Cyp19 aromatase promoter regions pII, pI.3 and pI.7 and estradiol production in human breast tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Aromatase inhibitors in breast cancer: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Overexpression of aromatase in transgenic male mice results in the induction of gynecomastia and other biochemical changes in mammary glands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Extranuclear steroid receptors: nature and actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

RETRACTED: Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Integration of the extranuclear and nuclear actions of estrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Novel nitro-oxy derivatives of celecoxib for the regulation of colon cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Nitrooxymethyl-substituted analogues of celecoxib: synthesis and pharmacological characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Regulation of estrogen receptor alpha-mediated transcription by a direct interaction with protein phosphatase 2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Estrogen receptor interaction with estrogen response elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

The changing global patterns of female breast cancer incidence and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

The Furoxan System: Design of Selective Nitric Oxide (NO) Donor Inhibitors of COX-2 Endowed with Anti-Aggregatory and Vasodilating Activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-010-0682-4

A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I

21 January 2018

1 reference

12 December 2020

Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.

1 reference

12 December 2020

Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1

1 reference

12 December 2020

Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model

1 reference

12 December 2020

Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice

1 reference

12 December 2020

Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer

1 reference

12 December 2020

NO-Donor COX-2 Inhibitors. New Nitrooxy-Substituted 1,5-Diarylimidazoles Endowed with COX-2 Inhibitory and Vasodilator Properties

1 reference

12 December 2020

Over expression of aromatase protein is highly related to MMPs levels in human breast carcinomas.

1 reference

12 December 2020

10.1007/S11010-010-0682-4

Identifiers

DOI

1 reference

13 September 2017

1 reference